Φορτώνει......
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
PURPOSE: Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients with advanced cancers. The objectives of this analys...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Chemother Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Berlin Heidelberg
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7870753/ https://ncbi.nlm.nih.gov/pubmed/33145616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04184-z |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|